Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the latest advances in therapeutics for essential thrombocythemia (ET), including LSD1 inhibitors and interferon therapy. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
